Aspects of Epidemiology, Pathogenesis and Natural History of Prostatic Cancer

  • F. H. Schröder
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

Prostatic cancer is the second most frequent cause of cancer death in males in most countries of the Western world, causing 9 to 10% of all cancer deaths every year. This death rate is exceeded only by lung cancer, and is followed by deaths from gastrointestinal tumors. Incidence and death from prostatic carcinoma are strongly age dependent, 75% of all prostatic carcinomas being diagnosed between the ages of 55 and 75 years.

Keywords

Placebo Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cantrell BB, DeKIerk DP, Eggleston JC, Boitnott JK, Walsh PC: Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol 1981 (125):516–520PubMedGoogle Scholar
  2. 2.
    Akazaki K, Stemmermann GN: Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawai. JNCI 1973 (50,5):1137–1144PubMedGoogle Scholar
  3. 3.
    Breslow N, Chan CW, Dhom G, Drury RAB, Franks LM, Gellei B, Lee YS, Lundsberg S, Sparke B, Sternby NH, Tulinius H: Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 1977 (20):680–688PubMedCrossRefGoogle Scholar
  4. 4.
    Zaridze DG, Boyle P, Smans M: International trends in prostatic cancer. Int J Cancer 1984 (33):223–230CrossRefGoogle Scholar
  5. 5.
    Wynder EL, Mabuchi K, Whitmore WF: Epidemiology of cancer of the prostate. Cancer 1971 (28):344–360PubMedCrossRefGoogle Scholar
  6. 6.
    Flanders WD: Review: prostate cancer epidemiology. The Prostate 1984 (5):621–629PubMedCrossRefGoogle Scholar
  7. 7.
    McNeal JE: Origin and evolution of prostatic carcinoma. In: Ablin RJ (ed) Prostatic Cancer. Marcel Dekker Inc, New York/Basle 1981 pp 43–50Google Scholar
  8. 8.
    Whitmore WF: The natural history of prostatic cancer. Cancer 1973 (32): 1104PubMedCrossRefGoogle Scholar
  9. 9.
    Mettlin C, Natarajan N, Murphy GP: Recent patterns of care of prostate cancer patients in the United States: results from the surveys of the American College of Surgeons Commission on Cancer. Int Adv Surg Oncol 1982 (5):277–321PubMedGoogle Scholar
  10. 10.
    Byar DP, Corle DK, Veterans Administration Cooperative Urological Research Group: VACURG randomized trial of radical prostatectomy for stage I and II prostate cancer. Urology 1981 (Suppl 12,4):7–11Google Scholar
  11. 11.
    Kramer SA, Cline WA, Farnham R, Carson CC, Cox EB, Hinshaw W, Paulson DF: Prognosis of patients with stage D1 prostatic carcinoma. J Urol 1981 (125):817PubMedGoogle Scholar
  12. 12.
    McCullough DL: Diagnosis and staging of prostatic cancer. In: Skinner DG, deKernion JB (eds) Genito-Urinary Cancer. Saunders, Philadelpha 1978 p 295Google Scholar
  13. 13.
    Catalona WJ, Scott WW: Carcinoma of the prostate. In: Harrison JH, Gittes RF, Perlmutter AD, Stamey TA, Walsh PC (eds) Campbell’s Urology. Saunders, Philadelphia 1979 p 1085Google Scholar
  14. 14.
    Byar D: VACURG studies on prostatic cancer and its treatment. In: Tannenbaum Lea M and Febger (eds) Urologie Pathology: The Prostate. New York 1977 pp 241–267Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • F. H. Schröder
    • 1
  1. 1.Department of UrologyErasmus UniversityRotterdamThe Netherlands

Personalised recommendations